14: Immunological products and vaccines

Please select a topic:

14.4 Vaccines and antisera

14.5 Immunoglobulins

Red = Hospital use only

Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee

Page 1 of 5

Date: 1.12.2012

14.4 Active immunity

BCG Intradermal vaccine (BCG SSI)

Adsorbed Diptheria, tetanus and pertussis (acellular, component) and inactivated polio vaccine (InfanrixIPV)

Adsorbed Diptheria (low dose), tetanus and pertussis (acellular, component) and inactivated polio vaccine
(Repevax)

Adsorbed Diptheria (low dose), tetanus and polio (inactivated) vaccine (Revaxis)

Diptheria, tetanus and pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilys tybe b
conjugate vaccine (Pedicael)

Haemophilus influenzae tybe b and meningitis group C vaccine (Menitorix)

Hepatitis A vaccine Occupational health only

Hepatitis B vaccine (Engerix B, HBvaxPRO, Engerix B Paediatric)

Influenza vaccine

Measles, mumps and rubella vaccine (MMR Vax Pro, Priorix)

Meningococcal group C vaccine (Meningitec, Menjugate)

Pneumococcal vaccine (Prevenar, Pneumovax II, Prevenar 13)

Varicella-zoster vaccine (Varivax)

Diagnostic agents

Tuberculin PPD 10 units/0.1ml injection

Tuberculin PPD 2 units/0.1ml injection

Prescribing Notes
Vaccines for the childhood immunisation schedule should be obtained from local health organisations or from
ImmForm (www.immform.dh.gov.uk)not to be prescribed on FP10 (HS21 in Northern Ireland; GP10 in Scotland;
WP10 in Wales).
Preterm birth
Babies born preterm should receive all routine immunisations based on their actual date of birth. The risk of apnoea
following vaccination is increased in preterm babies, particularly in those born at or before 28 weeks postmenstrual
age. If babies at risk of apnoea are in hospital at the time of their first immunisation, they should be monitored for
48 hours after immunisation. If a baby develops apnoea, bradycardia, or desaturation after the first immunisation,
the second immunisation should also be given in hospital with similar monitoring. Seroconversion may be
unreliable in babies born earlier than 28 weeks gestation or in babies treated with corticosteroids for chronic lung
disease; consideration should be given to testing for antibodies against Haemophilus influenzae (type b),
meningococcal C, and hepatitis B after primary immunisation.
Immunisation Schedule
Neonates at risk only

BCG Vaccine
See section 14.4, BCG Vaccines

Hepatitis B Vaccine
See section 14.4, Hepatitis B Vaccine

2 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis

Red = Hospital use only

Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee

Page 2 of 5

Date: 1.12.2012

(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)

First dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)

First dose

3 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis

(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)
Second dose

Meningococcal Group C Conjugate Vaccine

First dose

4 months

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis

(Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)
Third dose

Meningococcal Group C Conjugate Vaccine

Second dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)

Second dose

1213 months

Measles, Mumps and Rubella Vaccine, Live (MMR)

First dose

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)

Single booster dose

Haemophilus Type b Conjugate Vaccine and Meningococcal Group C

Conjugate Vaccine
Single booster dose

Between 3 years and

4 months, and 5
years

Adsorbed Diphtheria [low dose], Tetanus, Pertussis (Acellular,

Component) and Poliomyelitis (Inactivated) Vaccine
or
Adsorbed Diphtheria, Tetanus, Pertussis (Acellular, Component) and
Poliomyelitis (Inactivated) Vaccine
Single booster dose
Note: Preferably allow interval of at least 3 years after completing primary
course

Measles, Mumps and Rubella Vaccine, Live (MMR)

Second dose

1213 years (females

only)

1318 years

Human Papilloma Virus Vaccine

3 doses; second dose 12 months, and third dose 6 months after first dose (1)
Adsorbed Diphtheria [low dose], Tetanus, and Poliomyelitis (Inactivated)

Red = Hospital use only

Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee

Page 3 of 5

Date: 1.12.2012

Vaccine
Single booster dose
During adult life,
women of childbearing age
susceptible to rubella

Measles, Mumps and Rubella Vaccine, Live (MMR)

Women of child-bearing age who have not received 2 doses of a rubellacontaining vaccine or who do not have a positive antibody test for rubella
should be offered rubella immunisation (using the MMR vaccine)exclude
pregnancy before immunisation, but see also section 14.4, Measles, Mumps
and Rubella Vaccine

During adult life, if not

previously immunised

Adsorbed Diphtheria [low dose], Tetanus, and Poliomyelitis (Inactivated)

Vaccine
3 doses at intervals of 1 month
Booster dose at least 1 year after primary course and again 510 years later

The two human papilloma virus vaccines are not interchangeable and one vaccine product should be
used for the entire course.
(1)

Storage and use

Vaccines should be protected from light. Unused vaccine in multidose vials without preservative (most live virus
vaccines) should be discarded within 1 hour of first use; those containing a preservative (including oral poliomyelitis
vaccine) should be discarded within 3 hours or at the end of a session. Particular attention must be paid to
instructions on the use of diluents. Vaccines which are liquid suspensions or are reconstituted before use should be
adequately mixed to ensure uniformity of the material to be injected.

Red = Hospital use only

Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee

Page 4 of 5

Date: 1.12.2012

14.5 Immunoglobulins

Human normal immunoglobulin 5g injection (Vigam)

Human normal immunoglobulin 750mg (16%) (Subgam temporary alternative to human tetanus
immunoglobulin.

Human tetanus immunoglobulin 250 unit injection

Anti-D immunoglobulin 500 unit injection (BPL)

Anti-D immunoglobulin 300microgram/3ml syringe (Rhophylac)

Varicella Zoster immunoglobulin

Dose
Consult product literature
Prescribing notes

Supplies of Human Norman Immunoglobulin (Vigam) are strictky controlled throughout the UK and use is
limited to specific approved indications. Please contact pharmacy on ext 2316 prior to prescribing & order
using prescription form for immunoglobulin which can be found at
http://www.departments/medicines/prescriptions.html

Varicella Zoster immunoglobulin should be requested from HPA via On-call Microbiologist.

Red = Hospital use only

Green = GP & Hospital use. Drugs not classified as Red, Amber or Amber 2 are classified as Green by default
Amber 1 = Drugs with shared care agreement
Amber 2 = Initiated by Hospital specialist only
Gateshead Health NHS Foundation Trust
Drug Formulary
Drug & Therapeutics Committee

Page 5 of 5

Date: 1.12.2012